VentriPoint Diagnostics Ltd VPTDF

Primary Symbol: V.VPT

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Financing extension

<< Previous

Bullboard Posts

Next >>

Comment by jopatcloon May 16, 2024 6:49am

47 Views

Post# 36042772

RE:Financing extension

GranhamBWalk speculator FUD from Ventripoint for 2024 see his negative speculation verbal diare message.

Now Ventripoint has worldwide sales. Good comment see 100% ok for me.
@hassy @jgb1993 Here are some of the stats presented in the past (can be found at community wiki page). in US alone, GE has 40,000 cardiac ultrasound machines. assuming 10% of those are used for pediatric, we have 4,000 units which can benefit from VMS+. = 600M (using software revenue only at 15k per software). That's just US. EU, let's assume approx same size for all EU countries combined. Conservatively we have 1.2B markets to go- again, just pediatric only. Would we ever get there? No. We would be taken out WAY before that. As soon as we become the "standard of care", someone will buy us out- "similar" profiled tech has sold for 300M at early stage, and upward of 1b+ for slightly more mature company with more robust cashflow.

 			@Synergy If Hugh and the Ventripoint team can close those 6 orders that's $300,000 another months cash burn. If 4.0 is approved soon the interest in it should be known soon. Also please remember Ollie Hinkle Foundation advocacy could mean multiple buys once 4.0 is approved. The last major factor is Ascend collaboration with vpt can start bearing fruit. 
 			9
 			15 May 2024, 16:13

 					 
@AGS@Synergy Don't forget the 40% price increase ($50k to $70k) as Hugh confirmed on the call. Lot of meat on that VMS bone people. 
 			7
 			15 May 2024, 17:04

 					 
@CarlislerThat should be a little incentive for a buyer to get in early and run the gauntlet of hospital red tape quicker. 
 			3
 			15 May 2024, 18:11

 					 
@hassykeep in mind that each PO referred by Hugh is not necessarily 1 unit...hopefully we get a few multi unit orders!
 			5
 			 
 			about 11 hours ago

 					 
@jgb1993What’s the revenue model here: 50 units sold after 4.0 approval = 3.5 million Whats the residual per time the machine is used? How many are actually needed and will be used? I’m starting to not really see where this is becoming a ten bagger stock like some are claiming. Can someone set me straight?
 			0
 			about 7 hours ago

 					 
@Dirtdevil What hasn’t been talked about for a while is that VentriPoint will also get a fee back for each image that is produced. If I remember correctly, GEHC had over 2 billion images last year. Correct me if I’m wrong.
 			0
 			about 7 hours ago

 					 
@tooearlyThere is also the annual fee of 20% of the purchase price for software maintenance, fixes and minor upgrades. If they are smart, major upgrades like the step up to 4.0 will be an additional one time fee. Again, all this can be priced out and offered as a lease stream to those short on capital budgets. Large capital purchases often require high level executive approval. Lease streams not so much. A simple way to shorten the sales cycle in many instances.
 			0
 			about 7 hours ago

 					 
@hassy@jgb1993 Here are some of the stats presented in the past (can be found at community wiki page). in US alone, GE has 40,000 cardiac ultrasound machines. assuming 10% of those are used for pediatric, we have 4,000 units which can benefit from VMS+. = 600M (using software revenue only at 15k per software). That's just US. EU, let's assume approx same size for all EU countries combined. Conservatively we have 1.2B markets to go- again, just pediatric only. Would we ever get there? No. We would be taken out WAY before that. As soon as we become the "standard of care", someone will buy us out- "similar" profiled tech has sold for 300M at early stage, and upward of 1b+ for slightly more mature company with more robust cashflow. 
 			1
 			about 6 hours ago

 					 
@hassythat's why the focus has always been on becoming the "standard of care" by selling to KOL hospitals vs. random one off sale to local private clinic as some poster has suggested. our goal is not to become cash flow positive (would be great if we can get there..)
 			0
 			about 6 hours ago